LIFEVANTAGE CORP Deferred Revenue Recognized
LIFEVANTAGE CORP (LFVN) reported Deferred Revenue Recognized of -$400.00 thousand for the 12-month period ending 2026-06-30, per its 10-K filed 2026-08-27.
Financial Statements › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2026-08-27
- LIFEVANTAGE CORP contract with customer, liability, revenue recognized for the quarter ending 2026-03-31 was -$300.00K, a 400.00% decline year-over-year.
- LIFEVANTAGE CORP contract with customer, liability, revenue recognized for the quarter ending 2025-12-31 was $33.00K.
- LIFEVANTAGE CORP contract with customer, liability, revenue recognized for the quarter ending 2025-09-30 was $100.00K, a 50.00% decline year-over-year.
- LIFEVANTAGE CORP contract with customer, liability, revenue recognized for the quarter ending 2025-03-31 was $100.00K.
- LIFEVANTAGE CORP contract with customer, liability, revenue recognized for fiscal 2026 was -$400.00K, a 300.00% decline from fiscal 2025.
- LIFEVANTAGE CORP contract with customer, liability, revenue recognized for fiscal 2025 was $200.00K.
- LIFEVANTAGE CORP contract with customer, liability, revenue recognized for fiscal 2024 was -$26.00K.
- LIFEVANTAGE CORP contract with customer, liability, revenue recognized for fiscal 2023 was -$700.00K, a 450.00% decline from fiscal 2022.
| Period end | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 6 month | Contract with Customer, Liability, Revenue Recognized 9 month | Contract with Customer, Liability, Revenue Recognized 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$400.00K 10-K · filed 2026-08-27 | |||
| 2026-03-31 | -$300.00K 10-Q · filed 2026-05-06 | -$300.00K 10-Q · filed 2026-05-06 | ||
| 2025-12-31 | $33.00K 10-Q · filed 2026-02-04 | $24.00K 10-Q · filed 2026-02-04 | ||
| 2025-09-30 | $100.00K 10-Q · filed 2025-11-04 | |||
| 2025-06-30 | $200.00K 10-K · filed 2026-08-27 | |||
| 2025-03-31 | $100.00K 10-Q · filed 2026-05-06 | -$500.00K 10-Q · filed 2026-05-06 | ||
| 2024-12-31 | -$300.00K 10-Q · filed 2026-02-04 | -$500.00K 10-Q · filed 2026-02-04 | ||
| 2024-09-30 | $200.00K 10-Q · filed 2025-11-04 | |||
| 2024-06-30 | -$26.00K 10-K · filed 2025-09-04 | |||
| 2024-03-31 | -$200.00K 10-Q · filed 2025-05-06 | -$100.00K 10-Q · filed 2025-05-06 | ||
| 2023-12-31 | $100.00K 10-Q · filed 2025-02-05 | -$40.00K 10-Q · filed 2025-02-05 | ||
| 2023-09-30 | -$200.00K 10-Q · filed 2024-10-29 | |||
| 2023-06-30 | -$700.00K 10-K · filed 2024-08-28 | |||
| 2023-03-31 | $100.00K 10-Q · filed 2024-05-02 | $300.00K 10-Q · filed 2024-05-02 | ||
| 2022-12-31 | -$100.00K 10-Q · filed 2024-01-30 | -$100.00K 10-Q · filed 2024-01-30 | ||
| 2022-09-30 | -$100.00K 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | $200.00K 10-K · filed 2023-08-28 | |||
| 2019-06-30 | $500.00K 10-K · filed 2019-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |